ANGPT2 and hepatocellular carcinoma: Importantly, sorafenib is able to counteract this protumorigenic effect in Arid1a-deficient HCC by reducing H3K27ac deposition at the Ang-2 gene locus and, consequently, epigenetically downregulating Ang-2 expression.